MAP Stock Overview
Provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Microba Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.20 |
| 52 Week High | AU$0.33 |
| 52 Week Low | AU$0.14 |
| Beta | 2.71 |
| 1 Month Change | 2.63% |
| 3 Month Change | -25.00% |
| 1 Year Change | 14.71% |
| 3 Year Change | -52.44% |
| 5 Year Change | n/a |
| Change since IPO | -44.29% |
Recent News & Updates
Recent updates
Some Confidence Is Lacking In Microba Life Sciences Limited (ASX:MAP) As Shares Slide 29%
Mar 06
We're Hopeful That Microba Life Sciences (ASX:MAP) Will Use Its Cash Wisely
Aug 01We're Not Very Worried About Microba Life Sciences' (ASX:MAP) Cash Burn Rate
Apr 28Is Microba Life Sciences (ASX:MAP) In A Good Position To Invest In Growth?
Jul 05Shareholder Returns
| MAP | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 8.3% | -0.1% | 0.08% |
| 1Y | 14.7% | -16.8% | -3.9% |
Return vs Industry: MAP exceeded the Australian Healthcare industry which returned -16.8% over the past year.
Return vs Market: MAP exceeded the Australian Market which returned -3.9% over the past year.
Price Volatility
| MAP volatility | |
|---|---|
| MAP Average Weekly Movement | 12.0% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 16.3% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: MAP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MAP's weekly volatility (12%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Luke Reid | microba.com |
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome.
Microba Life Sciences Limited Fundamentals Summary
| MAP fundamental statistics | |
|---|---|
| Market cap | AU$87.33m |
| Earnings (TTM) | -AU$14.19m |
| Revenue (TTM) | AU$16.90m |
5.2x
P/S Ratio-6.2x
P/E RatioIs MAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAP income statement (TTM) | |
|---|---|
| Revenue | AU$16.90m |
| Cost of Revenue | AU$8.55m |
| Gross Profit | AU$8.35m |
| Other Expenses | AU$22.54m |
| Earnings | -AU$14.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 49.42% |
| Net Profit Margin | -83.97% |
| Debt/Equity Ratio | 3.4% |
How did MAP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 23:01 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Microba Life Sciences Limited is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tara Speranza | Bell Potter |
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |